RET Agonist BT44 CAS No.: 924759-42-2

Introduction to RET Agonist BT44

RET Agonist BT44 is a pharmaceutical product that has been designed to cater to the needs of patients suffering from certain types of cancers. As a manufacturer based in China, we take great pride in producing this drug using the most advanced manufacturing techniques and materials. Our experienced team of experts has been able to ensure that the end product is of the highest quality, making it capable of addressing the medical needs of patients better.

Product Description

RET Agonist BT44 is a small-molecule compound therapeutic agent that stimulates the RET (rearranged during transfection) pathway. As a result, it can successfully target RET kinase-driven tumors such as papillary thyroid carcinoma and non-small cell lung carcinoma. The drug selectively binds and activates the RET receptor, which causes downstream signaling events leading to inhibition of tumor cell growth and proliferation.

In addition, the drug has exhibited excellent oral bioavailability, good metabolic stability, and limited toxicity. This makes it an attractive candidate for further development and clinical trials.

Product Features

RET Agonist BT44 is a unique product that comes with a host of features that are sure to appeal to both patients and medical practitioners alike. Some of these features include:

1. Highly Specific to RET - The drug has been designed to specifically target the RET pathway, which makes it efficient in addressing the needs of patients suffering from RET kinase-driven tumors.

2. Lower Toxicity - RET Agonist BT44 has exhibited limited toxicity, making it a safer option for patients who need long-term treatments.

3. Good Bioavailability - The drug exhibits excellent oral bioavailability, making it easier for patients to take and for medical practitioners to prescribe.

4. Affordable - As a manufacturer located in China, we are able to produce RET Agonist BT44 at an affordable price point, which makes it more accessible to patients across the globe.

Product Benefits

By using RET Agonist BT44, patients can enjoy numerous benefits that set it apart from other cancer treatments available in the market. Some of these include:

1. Targeted Treatment - The drug is specifically designed to target RET kinase-driven tumors, which makes it more effective in treating this condition.

2. Fewer Side Effects - As RET Agonist BT44 exhibits lower toxicity, patients can suffer from fewer side effects when undergoing treatment.

3. Easier to Administer - As the drug exhibits excellent oral bioavailability, patients can take it easily and medical practitioners can prescribe it more conveniently.

4. Affordable Treatment Option - Our ability to produce RET Agonist BT44 at an affordable price point makes it a more accessible option for patients who may not have access to other more expensive treatments.

Conclusion

RET Agonist BT44 is a unique and effective drug that has been designed to address the needs of patients suffering from RET kinase-driven tumors. As a manufacturer, we are proud to offer this product at an affordable price point, making it more accessible to patients across the globe. With its excellent oral bioavailability, lower toxicity, and targeted treatment capabilities, RET Agonist BT44 is an attractive option for medical practitioners looking to provide their patients with safer and more effective cancer treatments.

Chemical Structure : RET Agonist BT44

CAS No.: 924759-42-2

 

RET Agonist BT44

Catalog No.: URK-V2368 Only Used For Lab.

Novel and specific RET agonist BT-44 is a small molecules for the treatment of experimental neuropathies, promote RET phosphorylation and selectively activates downstream cascades in the cells expressing GFL receptors.

Biological Activity

Novel and specific RET agonist BT-44 is a small molecules for the treatment of experimental neuropathies,

BT-44 selectively activated RET and intracellular pro-survival AKT and MAPK signaling pathways in immortalized cells.

BT-44 also protected cultured wild-type dopamine neurons from MPP+-induced toxicity

Physicochemical Properties

References

1, Journal of Parkinson's Disease, vol. 11, no. 3, pp. 1023-1046, 2021

2, Viisanen H, et al. Mol Pain. 2020 Jan-Dec;16:1744806920950866.

3, Renko JM, et al. J Parkinsons Dis. 2021;11(3):1023-1046.

URK-V2368_COA

URK-V2368_SDS

URK-V2368_TDS

 

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, and we do not provide products and services for any personal use!

Why choose us?

• We are committed to meeting the needs of our customers and exceeding their expectations with our Tyrosine Kinase Library products and services.
• Our company adheres to the concept of pragmatism and dedication, consistently provides customers with high-quality products and excellent service, and expects you to become our partner.
• Our Tyrosine Kinase Library products are competitively priced, without sacrificing quality or performance.
• Our company has been in line with the principle of 'based on scientific and technological innovation, striving for management, improving product quality and meeting customer needs'.
• We take customer feedback seriously and are always looking for ways to improve our Tyrosine Kinase Library products and services.
• Our quality policy is, deepen management, enhance customer satisfaction, continuous innovation, and create a first-class brand.
• Our Tyrosine Kinase Library products are widely used in research and development, pharmaceuticals, and other industries.
• Our objective will be to research and develop new products, continue to innovate, strive for perfection and deliver better RET Agonist BT44 CAS No.: 924759-42-2 to customers around the world.
• We use only the best quality materials and manufacturing processes to ensure that our Tyrosine Kinase Library products are of the highest possible quality.
• With the rapid development of the market attracting more and more participants, market competition has become increasingly complex and fierce.

Hot Tags: ret agonist bt44 cas no.: 924759-42-2, China ret agonist bt44 cas no.: 924759-42-2, agonists for dna repair, inhibitors for enzyme activity, epigenetic library for epigenetic analysis of epigenetic dysregulation, inhibitors for neurodegenerative diseases, epigenetic library for epigenetic regulation of cell metabolism, epigenetic library for epigenetic regulation of cell adhesion